Mylan Inc Under Pressure As Epipen Prices Skyrocket – ValueWalk Premium

Mylan Inc Under Pressure As Epipen Prices Skyrocket

You know its bad when even Martin Shkreli is accusing you of price gauging for needed medical goods. The pharma bro who jacked up the price of a drug 5,000 percent overnight and planned other mass drug hikes at Kalobios before he was removed, has called out Mylan Inc. (NASDAQ:MYL) for jacking up the price of Epipen. Shkreli told NBC:

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The top investors are reading ValuewalkPremium.

Click here to learn why

0